Fig. 4.Figure 4
Reconstitution of miR223-3p induces synthetic lethality in HR-deficient cancers. ( A ) QRT-PCR comparing the levels of miR223-3p and miR223-5p in Jurkat cells (HR-replete), MDA-MB-436 (BRCA1-mutant breast cancer cell line), and UWB1.289 (BRCA1-mutant ovarian cancer cell line). ( B ) QRT-PCR showing the expression of miR223-3p following transfection with miR223-3p in MDA-MB-436 breast cancer cells. ( C ) Clonogenic survival assay showing the number of colonies in MDA-MB-435, UWB1.289, and MCF7 (HR-replete breast cancer) cells upon transfection of miR223-3p. ( D ) Clonogenic survival assay in MDA-MB-436 after depletion of PARP1, CtIP, and PSO4. ( E ) Comparison of number of colonies in MDA-MB-436, and HCC-1937 (BRCA1-mutant breast cancer) cells in the presence of olaparib. ( F ) Clonogenic survival assay in HCC1937 cells after miR223-3p transfection.